Will Biogen’s new Alzheimer’s drug’s burden on Medicare be big, huge, or catastrophic?
(By Rachel Cohrs and J. Emory Parker for STAT) The Food and Drug Administration’s decision to grant wide-ranging approval to
Read More(By Rachel Cohrs and J. Emory Parker for STAT) The Food and Drug Administration’s decision to grant wide-ranging approval to
Read More(By Michelle Andrews for Kaiser Health News) The week before Brian Colvin was scheduled for shoulder surgery in November, he
Read More(By Drew Altman for Kaiser Family Foundation, published June 25, 2021) The fact that prescription drugs represent just 10% of national
Read More(By Katie Adams for Becker’s Hospital Review) More than $2.1 billion of Medicare Part B’s spending from 2017 to 2019 went
Read More(By Nick Moran for Becker’s Hospital Review) Point32Health may not cover Biogen’s new Alzheimer’s treatment, Aduhelm, for its commercial members unless
Read MoreThe bipartisan bill, The Ensuring Patient Access to Critical Breakthrough Products Act, would require Medicare to cover all breakthrough devices
Read More(By Nick Moran for Becker’s Hospital Review) State-based insurance marketplaces are now eligible for $20 million in new grant money
Read More(By Megan Molteni for STAT) For families and physicians grappling with the historic approval this month of the controversial Alzheimer’s
Read More(By Noam N. Levey and Phil Galewitz for NPR) The Biden administration is quietly engineering a series of expansions to
Read More(By Nick Moran for Becker’s Hospital Review) Five Blue Cross Blue Shield plans are funding and collaborating with Evio, a
Read More